Stockscreener 앱 받기
2.365
3.47%
-0.085
시간 외 거래:
1.76
-0.605
-25.58%
Biocardia Inc 주식(BCDA)의 최신 뉴스
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
BioCardia (NASDAQ:BCDA) Upgraded at Alliance Global Partners - Defense World
BioCardia upgraded to Buy from Neutral at Alliance Global Partners - Yahoo Finance
BioCardia, Inc. Announces Acceptance of CardiAMP HF Phase 3 Study Results for Presentation at ACC 2025 - Defense World
First Patient Dosed in Phase 1 Trial of GTB-3650On January 27, 2025, GT Biopharma, Inc. (NASDAQ:GTBP) made a significant stride in its clinical development efforts with the announcement that the first patient was dosed in the Phase 1 Trial of GTB-365 - Defense World
BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions - The Manila Times
BioCardia to Present CardiAMP Phase 3 Heart Failure Trial Results at ACC 2025 - StockTitan
Comparing Apogee Therapeutics (NASDAQ:APGE) and BioCardia (NASDAQ:BCDA) - Defense World
BioCardia (FRA:6JU0) Cyclically Adjusted FCF per Share : €-23.57 (As of Sep. 2024) - GuruFocus.com
Biocardia senior vice president Edward Gillis sells $6,514 in stock - Investing.com India
Biocardia CEO Peter Altman acquires shares worth $2,060 By Investing.com - Investing.com Australia
Biocardia CEO Peter Altman acquires shares worth $2,060 - Investing.com
BioCardia’s (BCDA) “Buy” Rating Reiterated at HC Wainwright - Defense World
BioCardia stock plunges to 52-week low of $1.81 amid market challenges - Investing.com
BioCardia, Inc. (NASDAQ:BCDA) Sees Significant Decrease in Short Interest - Defense World
BioCardia's SWOT analysis: cell therapy stock faces pivotal trial phase - Investing.com India
BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family - The Manila Times
BioCardia, Inc. Announces Commercial Availability of Morph DNA Steerable Introducer Product Family - Marketscreener.com
BioCardia's SWOT analysis: cell therapy stock faces pivotal trial phase By Investing.com - Investing.com Canada
Biocardia CEO Peter Altman buys $555 in common stock By Investing.com - Investing.com Nigeria
Biocardia CEO Peter Altman buys $555 in common stock - Investing.com
Microcatheters Market Surges to USD 1.53 Billion by 2032, Propelled by 5.53% CAGRReport by S&S Insider - GlobeNewswire
BioCardia Reports Successful Consultation with Japan’s PMDA on BCDA-01 RegistrationSunnyvale, California – December 4, 2024 – BioCardia, Inc. (NASDAQ: BCDA) has recently disclosed a significant achievement regarding its lead therapeutic asset, BC - Defense World
BioCardia's SWOT analysis: cell therapy firm's stock faces clinical trial hurdles - Investing.com India
BioCardia nears Japan registration for heart failure therapy By Investing.com - Investing.com Nigeria
BioCardia nears Japan registration for heart failure therapy - Investing.com India
BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure - The Manila Times
BioCardia's Heart Failure Treatment Gains Momentum with Promising PMDA Regulatory Path in Japan - StockTitan
Biocardia CEO Peter Altman acquires $2,524 in common stock By Investing.com - Investing.com Nigeria
Biocardia CEO Peter Altman acquires $2,524 in common stock - Investing.com
BioCardia (NASDAQ:BCDA) vs. Osiris Therapeutics (OTCMKTS:OSIR) Head-To-Head Analysis - Defense World
HC Wainwright Increases Earnings Estimates for BioCardia - Defense World
BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023) - Yahoo Finance
BioCardia stock plunges to 52-week low, touches $1.93 - Investing.com India
BioCardia stock plunges to 52-week low, touches $1.93 By Investing.com - Investing.com Nigeria
BioCardia, Inc. (NASDAQ:BCDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: BioCardia announces progress in heart therapy trials By Investing.com - Investing.com UK
BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthro - GuruFocus.com
BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... - Yahoo Finance
BioCardia Reports Q3 2024 Progress and Financials - TipRanks
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - The Manila Times
BioCardia Reports 35% Net Loss Improvement, Advances CardiAMP Trial Milestone | BCDA Stock News - StockTitan
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 - The Manila Times
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Cell therapy weekly: support for commercialization of complex therapies - RegMedNet
BioCardia concludes pivotal heart failure trial - Investing.com
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure - The Manila Times
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.59% - MSN
Beating Heart Patch Market to Make Great Impact in Near Future by 2031 |BIOCARDIA, INC., Athersys, Inc - openPR
1.03%
자본화:
|
볼륨(24시간):